

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Review of TA272; Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Final recommendation post consultation
The guidance should be transferred to the 'static guidance' list.

1. Background

This guidance was issued in January 2013.

At the GE meeting of 27 October 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance' list.

3. Rationale for selecting this proposal

This review did not identify new evidence for vinflunine that could be considered more robust, or relevant to UK clinical practice, than the evidence considered in TA272. Neither the marketing authorisation nor the list price of vinflunine has changed.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Royal College of Nursing</p> <p>Response to proposal: No comment</p>	<p>Comment from Technology Appraisals</p> <p>No action required.</p>
<p>Respondent: NHS England</p> <p>Response to proposal: Agree</p> <p>The Specialised Urology CRG are not aware of any new evidence in metastatic transitional cell, advanced metastatic carcinoma and agree that it is appropriate for the technology appraisal to be moved to the static list.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. The guidance will be transferred to the 'static guidance list'.</p>
<p>Respondent: Pierre Fabre</p> <p>Response to proposal:</p> <p>We would like to delay our response to this appraisal given the recent changes to NICE and the CDF and on completion of the CDF consultation we will consider if we are to re-submit with our new data.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. The guidance will be transferred to the 'static guidance list'. The company may still request to submit new data at a future date. This would be considered by NICE, and if accepted, a new review project proposal would be initiated.</p>
<p>Respondent: National Cancer Research Institute, Association of Cancer Physicians, Royal College of Physicians, Royal College of Radiologists</p> <p>Response to proposal: Agree</p> <p>In the absence of new evidence or a change in price, we support vinflunine being moved to the static list</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. The guidance will be transferred to the 'static guidance list'.</p>

Paper signed off by: Helen Knight, 14 December 2015

Contributors to this paper:

Technical Lead: Ahmed Elsada

Project Manager: Andrew Kenyon